Newly discovered biologic agent used for psoriasis treatment
Keywords:
psoriasis, traditional therapy and biologic agents, interleukin, tumour necrosis factor-αAbstract
Psoriasis is an autoimmune inflammatory skin disorder that affects 2–3% of the world's population. It has distinct features, such as accelerated keratinocyte proliferation and proinflammatory cytokines secretion. Topical, systemic, phototherapy, and biologic therapies are used in the treatment. Topical therapies are preferred over systemic medicines for mild to moderate psoriasis. Systemic therapies are best for severe pathological conditions. Immunosuppressants, biological agents, and recently licensed phosphodiesterase-4 (PDE4) inhibitors are some of the systemic therapies. Present therapies have a lot of drawbacks, and new discoveries in the pathogenesis of psoriasis are opening the way for novel therapeutics that target the disease at the molecular level. Multiple small molecules, PDE-4 inhibitors, biologics, and immunomodulators, as well as newly discovered Janus kinases (JAK) inhibitors, were found to be effective. This article focuses on many emerging treatments as well as presently approved psoriasis medications.
Downloads
References
A . Johnston, J . E . Gudjonsson, H . Sigmundsdottir, T. J . Love, H . Valdimarsson, Peripheral blood t cell responses to keratin peptides that share sequences with streptococcal m proteins are largely restricted to skin-homing CD8+ T cells. Clinical & Experimental Immunology, 138,83–93,2004. doi: 10.1111/j.1365-2249.2004.00600. x.
A. Menter, C. E. Griffiths, Current and future management of psoriasis. Lancet, 370 (9583), 272–284,2007. doi:10.1016/S0140-6736(07)61129-5.
C. E. Griffiths, J. N. Barker, Pathogenesis and clinical features of psoriasis. Lancet ,370,263-271,2007. doi:10.1016/S0140-6736(07) 61128-3
D. Y. Leung, J. B. Travers, R. Giorno, D. A. Norris, R. Skinner, J. Aelion, L. V. Kazemi, M. H. Kim, A. E. Trumble, M . Kotb, Evidence for a streptococcal superantigen driven process in acute guttate psoriasis. The Journal of Clinical Investigation, 96, 2106–2112,1995. doi: 10.1172/JCI118263
E . J. Samarasekera, L . Sawyer, D . Wonderling, R . Tucker, C . H. Smith, Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. The British Journal of Dermatology, 168 (5), 954–67,2013. doi:10.1111/bjd.12276.
G. Pasut, Pegylation of biological molecules and potential benefits: Pharmacological properties of certolizumab pegol. BioDrugs, 28(Suppl. 1), S15–S23,2014. doi: 10.1007/s40259-013-0064-z
J. G. Schlager, S. Rosumeck, R. N. Werner, A. Jacobs, J. Schmit, C. Schlager, Topical treatments for scalp psoriasis. The Cochrane Database of Systematic Reviews, 2 (2), 114-119,2016. doi:10.1002/14651858.CD009687.
Jani, J. R., Bajamal, A. H., Utomo, S. A., Parenrengi, M. A., Fauzi, A. A., Utomo, B., & Dwihapsari, Y. (2021). Correlation between magnetic resonance imaging (MRI) and dynamic mechanical analysis (DMA) in assessing consistency of brain tumor. International Journal of Health & Medical Sciences, 4(2), 260-266. https://doi.org/10.31295/ijhms.v4n2.1737
K. J. Mensah, E. M. Schwarz, C. T. Ritchlin, Altered bone remodeling in psoriatic arthritis. Current Rheumatology Report, 10,311–317,2008. doi: 10.1007/s11926-008-0050-5
L. Costa, A. Del, R. Puente, M. Peluso, M. S. Chimenti, V. Sabbatino, N. Girolimentto, Small molecule therapy for managing moderate to severe psoriatic arthritis, Expert Opinion Pharmacotherapy, 18(15),1557–1567,2017.
L. Peyrin, S. Danese, F. Cummings, R. Atreya, K. Greveson, B. Pieper, Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach". Expert Review of Gastroenterology & Hepatology, 13 (8), 731–738, 2019. doi:10.1080/17474124.2019.1645595
M . Galluzzo, S. D'adamio, L. Bianchi, M. Talamonti, Tildr akizumab for treating psoriasis. Expert Opinion on Biological Therapy, 17 (5), 645–657,2017.
M . Wittmann, P. S. Helliwell, Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases, Dermatology and Therapy, 3(1), 1–15,2013.
M. Feldmann, R. N. Maini, TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine, 9 (10), 1245– 50,2013. doi:10.1038/nm939.
N. U. Patel, N. C. Vera, E. R. Shealy, M. Wetzel, S. R. Feldman, A Review of the Use of Secukinumab for Psoriatic Arthritis". Rheumatology and Therapy, 4 (2), 233–246,2017. doi:10.1007/s40744-017-0076-0
P. Rutgeerts, W. J. Sandborn, B. G. Feagan, W. Reinisch, A. Olson, J. Johanns, S. Travers, D. Rachmilewitz, S. B. Hanauer, S. Lichtenstein , Infliximab for induction and maintenance therapy for ulcerative colitis. The New England Journal of Medicine, 353 (23), 2462–2476,2015. doi:10.1056/NEJMoa050516
R. Weller, A. A. John, Hunter, S. John, Clinical dermatology (4th ed.). Malden, MA: Blackwell, 54,70,2008.
S. Dogra, S. Yadav, Psoriasis in India prevalence and pattern. Indian Journal Dermatol Venereology Leprology, 76(6), 595-601,2010. doi: 10.4103/0378-6323.72443.
S. K. Raychaudhri, E. Maverakis, S. P. Raychaudhari, Diagnosis and classification of psoriasis. Autoimmunity Reviews, 13 ,(4-5), 490-5,2014.
S. R. Rapp, S. R. Feldman, M. L. Exum, A. B. Fleischer, D. M. Reboussin, Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology, 41,401-407,1999. N
S. Singh, R. Kroe, K. Canada, X. Zhu, et al. Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. 7(4),778– 91,2015.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
T. C. Lucka, D. Pathirana, A. Sammain, F. Bachmann, S. Rosumeck, R. Erdmann, J . Schmitt, H . Orawa, B. Rzany, Nast, and A. Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment. Journal of European Academy of Dermatology and Venereology, 26,1331–1344,2012. doi: 10.1111/j.1468-3083.2012. 04492.x
V. K. Raker, C. Becker, K. Steinbrink, The cAMP pathway as therapeutic target in autoimmune and inflammatory diseases, Frontier Immunology, 7, 123,2016.
Y. Cai, C. Fleming, J. Yan, Dermal T cells-a new player in the pathogenesis of psoriasis. International Immunopharmacology, 16 (3), 388–91,2013.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
